Referências
Principais artigos
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision. Geneva: WHO; 2022.Texto completo
Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528.Texto completo Resumo
Faraone SV, Banaschewski T, Coghill D, et al. The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.Texto completo Resumo
Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020 Feb/Mar;41 Suppl 2S:S35-S57.Texto completo Resumo
Artigos de referência
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision. Geneva: WHO; 2022.Texto completo
3. Schonwald A, Lechner E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr. 2006 Apr;18(2):189-95. Resumo
4. Barkley RA. Attention deficit hyperactivity disorder: a clinical handbook, 3rd ed. New York: Guilford; 2005.
5. Faraone SV, Biederman J, Jetton JG, et al. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol Med. 1997 Mar;27(2):291-300. Resumo
6. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):21-9. Resumo
7. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):37-44. Resumo
8. Faraone SV, Biederman J. Do attention deficit hyperactivity disorder and major depression share familial risk factors? J Nerv Ment Dis. 1997 Sep;185(9):533-41. Resumo
9. Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):997-1008. Resumo
10. Spencer TJ, Biederman MD, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007 Aug;32(8):631-42. Resumo
11. Pliszka SR, Carlson CL, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York, NY: Guilford; 1999.
12. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942-8.Texto completo Resumo
13. Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015 Mar;56(3):345-65. Resumo
14. Centers for Disease Control and Prevention. Data and statistics about ADHD. Oct 2023 [internet publication].Texto completo
15. Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014 Apr;43(2):434-42.Texto completo Resumo
16. Collishaw S. Annual research review: Secular trends in child and adolescent mental health. J Child Psychol Psychiatry. 2015 Mar;56(3):370-93. Resumo
17. Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am. 2004 Jun;27(2):225-32. Resumo
18. Sayal K, Prasad V, Daley D, et al. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018 Feb;5(2):175-86. Resumo
19. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the National Health Interview Survey. J Atten Disord. 2005 Nov;9(2):392-401. Resumo
20. Epstein JN, Willoughby M, Valencia EY, et al. The role of children's ethnicity in the relationship between teacher ratings of attention-deficit/hyperactivity disorder and observed classroom behavior. J Consult Clin Psychol. 2005 Jun;73(3):424-34. Resumo
21. Cénat JM, Blais-Rochette C, Morse C, et al. Prevalence and risk factors associated with attention-deficit/hyperactivity disorder among US black individuals: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Jan 1;78(1):21-8.Texto completo Resumo
22. Langley K, Holmans PA, van den Bree MB, et al. Effects of low birth weight, maternal smoking in pregnancy and social class on the phenotypic manifestation of attention deficit hyperactivity disorder and associated antisocial behavior: investigation in a clinical sample. BMC Psychiatry. 2007 Jun 20;7:26.Texto completo Resumo
23. DuPaul GJ, Gormley MJ, Laracy SD. Comorbidity of LD and ADHD: implications of DSM-5 for assessment and treatment. J Learn Disabil. 2013 Jan-Feb;46(1):43-51. Resumo
24. Dunn DW, Bourgeois BFD. Learning disabilities and ADHD in children with epilepsy. In: Duchowny M, Cross JH, Arzimanoglou A, eds. Pediatric epilepsy. New York, NY: McGraw Hill Medical; 2013:323-9.
25. Yao S, Kuja-Halkola R, Martin J, et al. Associations between attention-deficit/hyperactivity disorder and various eating disorders: a Swedish nationwide population study using multiple genetically informative approaches. Biol Psychiatry. 2019 Oct 15;86(8):577-86.Texto completo Resumo
26. Groenman AP, Janssen TWP, Oosterlaan J. Childhood psychiatric disorders as risk factor for subsequent substance abuse: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):556-69. Resumo
27. Fuller-Thomson E, Lewis DA, Agbeyaka S. Attention-deficit/hyperactivity disorder and alcohol and other substance use disorders in young adulthood: findings from a Canadian nationally representative survey. Alcohol Alcohol. 2022 May 10;57(3):385-95.Texto completo Resumo
28. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003 Jan;111(1):179-85. Resumo
29. Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry. 2011 Jul;24(4):280-5. Resumo
30. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1313-23. Resumo
31. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev. 2006 Aug;26(4):396-432. Resumo
32. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. Resumo
33. Thapar A. Discoveries on the genetics of ADHD in the 21st century: new findings and their implications. Am J Psychiatry. 2018 Oct 1;175(10):943-50.Texto completo Resumo
34. Martin J, O'Donovan MC, Thapar A, et al. The relative contribution of common and rare genetic variants to ADHD. Transl Psychiatry. 2015 Feb 10;5(2):e506.Texto completo Resumo
35. Nigg J, Nikolas M, Burt SA. Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):863-73. Resumo
36. Walton E, Pingault JB, Cecil CA, et al. Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study. Mol Psychiatry. 2017 Feb;22(2):250-6. Resumo
37. Thapar A, O'Donovan MC, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet. 2005 Oct 15;14 Spec No 2:R275-82.Texto completo Resumo
38. Groen-Blokhuis MM, Middeldorp CM, van Beijsterveldt CE, et al. Evidence for a causal association of low birth weight and attention problems. J Am Acad Child Adolesc Psychiatry. 2011 Dec;50(12):1247-54. Resumo
39. Sourander A, Sucksdorff M, Chudal R, et al. Prenatal cotinine levels and ADHD among offspring. Pediatrics. 2019 Mar;143(3):e20183144.Texto completo Resumo
40. Class QA, Rickert ME, Larsson H, et al. Fetal growth and psychiatric and socioeconomic problems: population-based sibling comparison. Br J Psychiatry. 2014 Nov;205(5):355-61.Texto completo Resumo
41. Lahat E, Heyman E, Livne A, et al. Iron deficiency in children with attention deficit hyperactivity disorder. Isr Med Assoc J. 2011 Sep;13(9):530-3. Resumo
42. Froehlich TE, Anixt JS, Loe IM, et al. Update on environmental risk factors for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2011 Sep;13(9):333-44. Resumo
43. Rodriguez A, Bohlin G. Are maternal smoking and stress during pregnancy related to ADHD symptoms in children? J Child Psychol Psychiatry. 2005 Mar;26(3):246-54. Resumo
44. Nilsen FM, Tulve NS. A systematic review and meta-analysis examining the interrelationships between chemical and non-chemical stressors and inherent characteristics in children with ADHD. Environ Res. 2020 Jan;180:108884. Resumo
45. Björkenstam E, Björkenstam C, Jablonska B, et al. Cumulative exposure to childhood adversity, and treated attention deficit/hyperactivity disorder: a cohort study of 543 650 adolescents and young adults in Sweden. Psychol Med. 2018 Feb;48(3):498-507. Resumo
46. Knopik VS, Sparrow EP, Madden PA, et al. Contributions of parental alcoholism, prenatal substance exposure, and genetic transmission to child ADHD risk: a female twin study. Psychol Med. 2005 May;35(5):625-35. Resumo
47. Kennedy M, Kreppner J, Knights N, et al. Early severe institutional deprivation is associated with a persistent variant of adult attention-deficit/hyperactivity disorder: clinical presentation, developmental continuities and life circumstances in the English and Romanian Adoptees study. J Child Psychol Psychiatry. 2016 Oct;57(10):1113-25.Texto completo Resumo
48. Kreppner JM, O'Connor TG, Rutter M. Can inattention/overactivity be an institutional deprivation syndrome? J Abnorm Child Psychol. 2001 Dec;29(6):513-28. Resumo
49. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020 Feb 8;395(10222):450-62. Resumo
50. Greenhill LL. Stimulant medication treatment of children with attention deficit hyperactivity disorder. In: Jensen PS, Cooper JR, eds. Attention deficit hyperactivity disorder: state of science. best practices. Kingston, NH: Civic Research Institute 2002:9-1-9-27.
51. Wilens TE. Mechanism of action of agents used in attention deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67 Suppl 8:32-8. Resumo
52. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Resumo
53. Sengupta SM, Grizenko N, Thakur GA, et al. Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. J Psychiatry Neurosci. 2012 Feb;37(2):129-37.Texto completo Resumo
54. Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011 Dec 4;44(1):78-84. Resumo
55. Wargelius HL, Malmberg K, Larsson JO, et al. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr Genet. 2012 Feb;22(1):42-5. Resumo
56. Cortese S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012 Sep;16(5):422-33. Resumo
57. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005 Jun 1;57(11):1336-46. Resumo
58. Castellanos FX, Sonuga-Barke EJ, Milham MP, et al. Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci. 2006 Mar;10(3):117-23. Resumo
59. Strauß M, Ulke C, Paucke M, et al. Brain arousal regulation in adults with attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res. 2018 Mar;261:102-8. Resumo
60. Metin B, Roeyers H, Wiersema JR, et al. A meta-analytic study of event rate effects on Go/No-Go performance in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012 Dec 15;72(12):990-6. Resumo
61. Valera EM, Faraone SV, Murray KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007 Jun 15;61(12):1361-9. Resumo
62. Duerden EG, Tannock R, Dockstader C. Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. Brain Res. 2012 Mar 22;1445:82-91. Resumo
63. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry. 2017 Apr;4(4):310-9.Texto completo Resumo
64. Nakao T, Radua J, Rubia K, et al. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry. 2011 Nov;168(11):1154-63. Resumo
65. Lukito S, Norman L, Carlisi C, et al. Comparative meta-analyses of brain structural and functional abnormalities during cognitive control in attention-deficit/hyperactivity disorder and autism spectrum disorder. Psychol Med. 2020 Apr;50(6):894-919. Resumo
66. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005 Jun 1;57(11):1273-84. Resumo
67. Mills KL, Bathula D, Dias TG, et al. Altered cortico-striatal-thalamic connectivity in relation to spatial working memory capacity in children with ADHD. Front Psychiatry. 2012 Jan 25;3:2.Texto completo Resumo
68. Gallo EF, Posner J. Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms. Lancet Psychiatry. 2016 Jun;3(6):555-67. Resumo
69. Posner J, Park C, Wang Z. Connecting the dots: a review of resting connectivity MRI studies in attention-deficit/hyperactivity disorder. Neuropsychol Rev. 2014 Mar;24(1):3-15. Resumo
70. Tomasi D, Volkow ND. Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012 Mar 1;71(5):443-50. Resumo
71. Cortese S, Castellanos FX. Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep. 2012 Oct;14(5):568-78. Resumo
72. Chen L, Hu X, Ouyang L, et al. A systematic review and meta-analysis of tract-based spatial statistics studies regarding attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2016 Sep;68:838-47. Resumo
73. Szatmari P, Saigal S, Rosenbaum P, et al. Psychiatric disorders at five years among children with birth weights less than 1000g: a regional perspective. Dev Med Child Neurol. 1990 Nov;32(11):954-62. Resumo
74. Mick E, Biederman J, Prince J, et al. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002 Feb;23(1):16-22. Resumo
75. Masur D, Shinnar S, Cnaan A, et al; Childhood Absence Epilepsy Study Group. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013 Oct 29;81(18):1572-80.Texto completo Resumo
76. Avella-Garcia CB, Julvez J, Fortuny J, et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. Int J Epidemiol. 2016 Dec 1;45(6):1987-96.Texto completo Resumo
77. Brandlistuen RE, Ystrom E, Nulman I, et al. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol. 2013 Dec;42(6):1702-13.Texto completo Resumo
78. Ji Y, Azuine RE, Zhang Y, et al. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry. 2020 Feb 1;77(2):180-9.Texto completo Resumo
79. Rutter M, Cox A, Tupling C, et al. Attainment and adjustment in two geographical areas. 1 - The prevalence of psychiatric disorders. Br J Psychiatry. 1975 Jun;126:493-509. Resumo
80. Biederman J, Milberger S, Faraone SV, et al. Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry. 1995 Jun;52(6):464-70. Resumo
81. Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter's index of adversity in a sample of boys and girls with and without ADHD. Am J Psychiatry. 2002 Sep;159(9):1556-62.Texto completo Resumo
82. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006 Dec;114(12):1904-9.Texto completo Resumo
83. Max JE, Arndt S, Castillo CS, et al. Attention-deficit hyperactivity disorder symptomatology after traumatic brain injury: a prospective study. J Am Acad Child Adolesc Psychiatry. 1998 Aug;37(8):841-7. Resumo
84. Adeyemo BO, Biederman J, Zafonte R, et al. Mild traumatic brain injury and ADHD: a systematic review of the literature and meta-analysis. J Atten Disord. 2014 Oct;18(7):576-84. Resumo
85. Cortese S, Angriman M, Lecendreux M, et al. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother. 2012 Oct;12(10):1227-40. Resumo
86. Tseng PT, Cheng YS, Yen CF, et al. Peripheral iron levels in children with attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Sci Rep. 2018 Jan 15;8(1):788.Texto completo Resumo
87. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):991-1000. Resumo
88. Chang JP, Su KP, Mondelli V, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology. 2018 Feb;43(3):534-45.Texto completo Resumo
89. Gillies D, Leach MJ, Perez Algorta G. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD007986. Resumo
90. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528.Texto completo Resumo
91. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. Sep 2019 [internet publication].Texto completo
92. Faraone SV, Banaschewski T, Coghill D, et al. The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.Texto completo Resumo
93. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1015-37. Resumo
94. Chang LY, Wang MY, Tsai PS. Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis. Pediatrics. 2016 Mar;137(3):e20152749. Resumo
95. Pineda DA, Puerta IC, Aguirre DC, et al. The role of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. Pediatr Neurol. 2007 Jun;36(6):373-81. Resumo
96. Weiler MD, Bernstein JH, Bellinger DC, et al. Processing speed in children with attention deficit/hyperactivity disorder, inattentive type. Child Neuropsychol. 2000 Sep;6(3):218-34. Resumo
97. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder. Circulation. 2008 May 6;117(18):2407-23.Texto completo Resumo
98. de Boo GM, Prins PJ. Social incompetence in children with ADHD: possible moderators and mediators in social-skills training. Clin Psychol Rev. 2007 Jan;27(1):78-97. Resumo
99. Steiner H, Remsing L; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):126-41.Texto completo Resumo
100. Richardson LP, McCauley E, Grossman DC, et al. Evaluation of the patient health questionnaire-9 item for detecting major depression among adolescents. Pediatrics. 2010 Dec;126(6):1117-23. Resumo
101. Woolf AD, Goldman R, Bellinger DC. Update on the clinical management of childhood lead poisoning. Pediatr Clin North Am. 2007 Apr;54(2):271-94. Resumo
102. Sandoval C, Jayabose S, Eden AN. Trends in diagnosis and management of iron deficiency during infancy and early childhood. Hematol Oncol Clin North Am. 2004 Dec;18(6):1423-38. Resumo
103. Streissguth AP, O'Malley K. Neuropsychiatric implications and long-term consequences of fetal alcohol spectrum disorders. Semin Clin Neuropsychiatry. 2000 Jul;5(3):177-90. Resumo
104. Wattendorf DJ, Muenke M. Fetal alcohol spectrum disorders. Am Fam Physician. 2005 Jul 15;72(2):279-82;285. Resumo
105. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989 Apr;160(4):863-8. Resumo
106. Kaufman DM. Congenital cerebral impairments. In: Kaufman DM. Clinical neurology for psychiatrists. 6th ed. Bronx, NY: Elsevier; 2007:295-311.
107. McKeown NJ, Tews MC, Gossain VV, et al. Hyperthyroidism. Emerg Med Clin North Am. 2005 Aug;23(3):669-85, viii. Resumo
108. Meltzer LJ. Mindell JA. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am. 2006 Dec;29(4):1059-76. Resumo
109. Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020 Feb/Mar;41 Suppl 2S:S35-S57.Texto completo Resumo
110. Levy SJ, Williams JF, Committee On Substance Use And Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016 Jul;138(1):e20161211.Texto completo Resumo
111. Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines (4.1th ed). 2020 [internet publication].Texto completo
112. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999 Dec:56(12):1073-86.Texto completo Resumo
113. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit hyperactivity disorder. Pediatrics. 2004 Apr;113(4):754-61. Resumo
114. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):989-1002. Resumo
115. Vaughan B, Kratochvil CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55. Resumo
116. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-38.Texto completo Resumo
117. National Institute for Health and Care Excellence. Clinical knowledge summaries. Scenario: management of attention deficit hyperactivity disorder (ADHD). Jan 2021 [internet publication].Texto completo
118. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284-1293. Resumo
119. Jones K, Daley D, Hutchings J, et al. Efficacy of the Incredible Years Programme as an early intervention for children with conduct problems and ADHD: long-term follow-up. Child Care Health Dev. 2008 May;34(3):380-90. Resumo
120. Greenhill LL, Posner K, Vaughan BS, et al. Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):347-66, ix. Resumo
121. Harstad E, Shults J, Barbaresi W, et al. α2-adrenergic agonists or stimulants for preschool-age children with attention-deficit/hyperactivity disorder. JAMA. 2021 May 25;325(20):2067-75. Resumo
122. Santosh P. Stimulant medication to treat attention-deficit/hyperactivity disorder. BMJ. 2017 Jul 14;358:j2945. Resumo
123. Storebø OJ, Storm MRO, Pereira Ribeiro J, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. Resumo
124. Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016 Feb 4;(2):CD009996.Texto completo Resumo
125. Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018 May 9;(5):CD012069.Texto completo Resumo
126. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010 Jan;19(4):353-64. Resumo
127. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007 Aug;28(4):265-73. Resumo
128. Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-32.Texto completo Resumo
129. Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis. JAMA Pediatr. 2019 Jul 1;173(7):630-39.Texto completo Resumo
130. Greenhill LL, Swanson JM, Hechtman L, et al. Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2020 Aug;59(8):978-89. Resumo
131. Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019 Mar 21;380(12):1128-38.Texto completo Resumo
132. Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry. 2019 Aug;6(8):651-8.Texto completo Resumo
133. Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014 Aug;55(8):878-85. Resumo
134. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Jun 2023 [internet publication].Texto completo
135. Man KKC, Häge A, Banaschewski T, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry. 2023 May;10(5):323-33. Resumo
136. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011 Nov 17;365(20):1896-904. Resumo
137. Liang EF, Lim SZ, Tam WW, et al. The Effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): systematic review, meta-analysis, and meta-regression. Int J Environ Res Public Health. 2018 Aug 20;15(8):1789.Texto completo Resumo
138. Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psychiatry. 2019 Oct;28(10):1283-93. Resumo
139. Shin JY, Roughead EE, Park BJ, et al. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016 May 31;353:i2550.Texto completo Resumo
140. Brams M, Moon E, Pucci M, et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010 Aug;26(8):1809-25. Resumo
141. Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan;12(4):308-15. Resumo
142. Medicines and Healthcare products Regulatory Agency. Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations. Sep 2022 [internet publication].Texto completo
143. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000 Jan;3(4):200-11.
144. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Resumo
145. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;(6):CD007990.Texto completo Resumo
146. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84. Resumo
147. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001 Nov;108(5):E83. Resumo
148. Buitelaar J, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007 Mar 1;61(5):694-9. Resumo
149. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. Resumo
150. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007 Mar;41(3):222-30. Resumo
151. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008 Jun;165(6):721-30.Texto completo Resumo
152. Scott NG, Ripperger-Suhler J, Rajab MH, et al. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2010 Jun;20(3):197-203. Resumo
153. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007 Sep;46(9):1119-27. Resumo
154. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Atomoxetine. Jul 2017 [internet publication].Texto completo
155. Liu Q, Zhang H, Fang Q, et al. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials. J Clin Exp Neuropsychol. 2017 Nov;39(9):854-65. Resumo
156. Banaschewski T, Roessner V, Dittman RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):I102-16. Resumo
157. Rains A, Scahill L, Hamrin V. Nonstimulant medications for the treatment of ADHD. J Child Adolesc Psychiatr Nurs. 2006 Feb;19(1):44-7. Resumo
158. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008 Jan;121(1):e73-84. Resumo
159. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85. Resumo
160. Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65. Resumo
161. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010 Sep;24(9):755-68. Resumo
162. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011 Jun;127(6):e1406-13. Resumo
163. Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr Drugs. 2011 Oct 1;13(5):329-36. Resumo
164. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10);1314-21. Resumo
165. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005 Apr 1;57(7):793-801. Resumo
166. Langberg JM, Arnold LE, Flowers AM, et al. Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol. 2010;39(2):220-33. Resumo
167. Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016 May 10;315(18):1997-2008. Resumo
168. Storebø OJ, Elmose Andersen M, Skoog M, et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2019 Jun 21;(6):CD008223.Texto completo Resumo
169. Asarnow JR, Rozenman M, Wiblin J, et al. Integrated medical-behavioral care compared with usual primary care for child and adolescent behavioral health: a meta-analysis. JAMA Pediatr. 2015 Oct;169(10):929-37.Texto completo Resumo
170. Coughlin CG, Cohen SC, Mulqueen JM, et al. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015 Oct;25(8):611-7. Resumo
171. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):147-58. Resumo
172. Harstad E, Levy S, Committee on Substance Abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014 Jul;134(1):e293-301.Texto completo Resumo
173. Clinical Guideline Committee (CGC) Members; ASAM Team; AAAP Team; IRETA Team. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun 01;18(1):1-56.Texto completo
174. Barkla XM, McArdle PA, Newbury-Birch D. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? a systematic review of the literature. BMC Psychiatry. 2015 Oct 30;15:270.Texto completo Resumo
175. Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Sep;54(9):728-36. Resumo
176. Chen Q, Sjölander A, Runeson B, et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014 Jun 18;348:g3769.Texto completo Resumo
177. Huang KL, Wei HT, Hsu JW, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry. 2018 Apr;212(4):234-8.Texto completo Resumo
178. Liang SH, Yang YH, Kuo TY, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study. Res Dev Disabil. 2018 Jan;72:96-105.Texto completo Resumo
179. Man KK, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry. 2017 Oct 1;74(10):1048-55. Resumo
180. Valdes AM, Walter J, Segal E, et al. Role of the gut microbiota in nutrition and health. BMJ. 2018 Jun 13;361:k2179.Texto completo Resumo
181. Cagigal C, Silva T, Jesus M, et al. Does diet affect the symptoms of ADHD? Curr Pharm Biotechnol. 2019;20(2):130-6. Resumo
182. Pelsser LM, Frankena K, Toorman J, et al. Diet and ADHD, reviewing the evidence: a systematic review of meta-analyses of double-blind placebo-controlled trials evaluating the efficacy of diet interventions on the behavior of children with ADHD. PLoS One. 2017;12(1):e0169277.Texto completo Resumo
183. Johnstone JM, Hatsu I, Tost G, et al. Micronutrients for attention-deficit/hyperactivity disorder in youths: a placebo-controlled randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2022 May;61(5):647-61.Texto completo Resumo
184. Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev. 2014 Aug;34(6):496-505. Resumo
185. Nigg JT, Lewis K, Edinger T, et al. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):86-97.e8. Resumo
186. Robinette LM, Hatsu IE, Johnstone JM, et al. Fruit and vegetable intake is inversely associated with severity of inattention in a pediatric population with ADHD symptoms: the MADDY Study. Nutr Neurosci. 2023 Jun;26(6):572-81.Texto completo Resumo
187. Li L, Taylor MJ, Bälter K, et al. Attention-deficit/hyperactivity disorder symptoms and dietary habits in adulthood: A large population-based twin study in Sweden. Am J Med Genet B Neuropsychiatr Genet. 2020 Dec;183(8):475-85.Texto completo Resumo
188. Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994 Feb 3;330(5):301-7.Texto completo Resumo
189. Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children. a meta-analysis. JAMA. 1995 Nov 22-29;274(20):1617-21. Resumo
190. Centers for Disease Control and Prevention. Childhood Nutrition Facts. Aug 2022 [internet publication].Texto completo
191. Evans S, Ling M, Hill B, et al. Systematic review of meditation-based interventions for children with ADHD. Eur Child Adolesc Psychiatry. 2018 Jan;27(1):9-27. Resumo
192. Karpouzis F, Bonello R, Pollard H. Chiropractic care for paediatric and adolescent attention-deficit/hyperactivity disorder: a systematic review. Chiropr Osteopat. 2010 Jun 2;18:13.Texto completo Resumo
193. American Academy of Pediatrics. Subcommittee on attention-deficit/hyperactivity disorder and committee on quality improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct;108(4):1033-44. Resumo
194. ClinicalTrials.gov. KP415 classroom study in children (6-12 years of age) with ADHD. NCT03292952. Jun 2020 [internet publication].Texto completo
195. Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021 Apr;43(4):684-700.Texto completo Resumo
196. Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020 Aug;42(8):1452-66.Texto completo Resumo
197. Nasser A, Kosheleff AR, Hull JT, et al. Translating attention-deficit/hyperactivity disorder rating scale-5 and Weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (viloxazine extended-release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021 Apr;31(3):214-26.Texto completo Resumo
198. McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):403-11.e3.Texto completo Resumo
199. National Institute for Health and Care Excellence. Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. Jan 2023 [internet publication].Texto completo
200. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990 Jul;29(4):546-57. Resumo
201. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of ADHD and related disorders. Arch Gen Psychiatry. 1996 May;53(5):437-46. Resumo
202. Curry AE, Yerys BE, Metzger KB, et al. Traffic crashes, violations, and suspensions among young drivers with ADHD. Pediatrics. 2019 Jun;143(6):e20182305.Texto completo Resumo
203. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004 Feb;45(2):195-211. Resumo
204. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adoles Pscyhiatry. 2006 Feb;45(2):192-202. Resumo
205. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004 Feb;14(2):65-73. Resumo
206. Kidwell KM, Van Dyk TR, Lundahl A, et al. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015 Dec;136(6):1144-53. Resumo
207. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005 Aug;90(8):801-6. Resumo
208. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1015-27. Resumo
209. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996 Nov;35(11):1460-9. Resumo
210. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006 Apr 6;354(14):1445-8.Texto completo Resumo
211. Hammerness PG, Perrin JM, Shelley-Abrahamson R, et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90. Resumo
212. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):614-9. Resumo
213. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention-deficit hyperactivity disorder. Pediatrics. 2002 Aug;110(2 Pt 1):258-66. Resumo
214. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit hyperactivity disorder. Pediatrics. 2001 Oct;108(4):883-92. Resumo
215. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999 Apr;56(4):330-6.Texto completo Resumo
216. Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. J Dev Behav Pediatr. 1990 Oct;11(5):269-71. Resumo
217. Winhusen TM, Lewis DF, Riggs PD, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011 Oct;21(5):455-63. Resumo
218. Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics. 2014 Jun;133(6):1070-80.Texto completo Resumo
219. Nigg JT, Johnstone JM, Musser ED, et al. Attention-deficit/hyperactivity disorder (ADHD) and being overweight/obesity: new data and meta-analysis. Clin Psychol Rev. 2016 Feb;43:67-79. Resumo
220. Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry. 2016 Jan;173(1):34-43.Texto completo Resumo
221. Østergaard SD, Dalsgaard S, Faraone SV, et al. Teenage parenthood and birth rates for individuals with and without attention-deficit/hyperactivity disorder: a nationwide cohort study. J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):578-84.e3. Resumo
222. Hua MH, Huang KL, Hsu JW, et al. Early pregnancy risk among adolescents with ADHD: a nationwide longitudinal study. J Atten Disord. 2021 Jul;25(9):1199-1206. Resumo
223. Skoglund C, Kopp Kallner H, Skalkidou A, et al. Association of attention-deficit/hyperactivity disorder with teenage birth among women and girls in Sweden. JAMA Netw Open. 2019 Oct 2;2(10):e1912463.Texto completo Resumo
224. Pohlabeln H, Rach S, De Henauw S, et al. Further evidence for the role of pregnancy-induced hypertension and other early life influences in the development of ADHD: results from the IDEFICS study. Eur Child Adolesc Psychiatry. 2017 Aug;26(8):957-67. Resumo
225. Yeh JY, Hou TY, Tseng WT, et al. Association between attention deficit hyperactivity disorder and risk of burn injury: a propensity-matched cohort study. Neuropsychiatr Dis Treat. 2020;16:1249-55.Texto completo Resumo
226. Nelson LD, Guskiewicz KM, Marshall SW, et al. Multiple self-reported concussions are more prevalent in athletes with ADHD and learning disability. Clin J Sport Med. 2016 Mar;26(2):120-7. Resumo
227. Chang Z, Lichtenstein P, D'Onofrio BM, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014 Mar;71(3):319-25.Texto completo Resumo
228. Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38(1):113-28. Resumo
229. Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012 Feb;169(2):167-77.Texto completo Resumo
230. Rashid MA, Lovick S, Llanwarne NR. Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. Fam Pract. 2018 Mar 27;35(2):142-50.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal